Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
None
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM

  • 8 views
  • 03 Mar, 2021
  • 58 locations
None
Elotuzumab Pomalidomide & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durability of responses which is essential to improving outcomes following second ASCT.

pomalidomide
dexamethasone
pomalyst
elotuzumab
stem cell transplantation
  • 4 views
  • 10 Jul, 2021
  • 5 locations
None
Selinexor and Backbone Treatments of Multiple Myeloma Patients

: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM Arm 8: Selinexor + dexamethasone + ixazomib (SNd) Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd) Arm

monoclonal protein
immunomodulatory imide drug
serum proteins
elotuzumab
electrophoresis
  • 57 views
  • 07 May, 2021
  • 24 locations
None
Daratumumab Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

myeloma in the last couple of years, including, Elotuzumab, Panobinostat, Ixazomib, carfilzomib and Pomalidomide. However, most of these drugs either do not have good single agent activity or still

  • 81 views
  • 22 Jan, 2021
  • 3 locations
None
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell

  • 0 views
  • 01 Mar, 2021
  • 1 location
None
Immuno-Oncology Drugs Elotuzumab Anti-LAG-3 and Anti-TIGIT

allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the

monoclonal protein
kappa light chain
pomalyst
immunomodulatory imide drug
elotuzumab
  • 0 views
  • 19 Sep, 2021
  • 8 locations
None
Dexamethasone Elotuzumab and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

This phase II trial studies how well dexamethasone, elotuzumab, pomalidomide work in treating patients with multiple myeloma that has not responded to previous treatment. Drugs used in

measurable disease
monoclonal antibody therapy
pomalidomide
monoclonal protein
growth factor
  • 0 views
  • 06 Mar, 2021
  • 1 location
None
Umbilical Cord Blood-Derived Natural Killer Cells Elotuzumab Lenalidomide and High Dose Melphalan Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

This phase II trial studies the side effects and best dose of umbilical cord blood-derived natural killer cells when given together with elotuzumab, lenalidomide, and high dose melphalan before

monoclonal antibody therapy
monoclonal protein
melphalan
revlimid
tumor cells
  • 28 views
  • 22 Jul, 2021
  • 1 location
None
Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions

studied includes: Blinatumomab (BLINCYTO, Amgen Inc.), Daratumumab (DARZALEX, Janssen Biotech, Inc.), Elotuzumab (EMPLICIT, Bristol-Myers Squibb Company), Gemtuzumab (MYLOTARG, Pfizer Inc.), Obinutuzumab

  • 1 views
  • 25 Jan, 2021
  • 1 location